Skip to main content
. 2020 Sep 17;11(9):773. doi: 10.1038/s41419-020-02986-w

Fig. 1. ABTL0812 reduces neuroblastoma cell lines proliferation in vitro and tumour growth in vivo.

Fig. 1

a, b Dose-response curves for cisplatin (a) and ABTL0812 (b) in six neuroblastoma cell lines. Cells were treated with ABTL0812 or cisplatin for 72 h at the indicated concentrations, then fixed with 1% glutaraldehyde and stained with crystal violet. c Schematic representation of the in vivo experiment using a neuroblastoma xenograft model. d Tumour volume of mice treated with vehicle, ABTL0812 or cisplatin measured at 23 days (n = 10/group). e Average weight of resected tumours. f Correlation between tumour weight and tumour volume. Data is presented as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01 ABTL0812 vs. vehicle; $p ≤ 0.05, $$p ≤ 0.01 cisplatin vs. vehicle.